Sophia Genetics Sa · NASDAQ:SOPH
Sophia Genetics Sa — Q4 2025 Earnings Presentation
17 slides from Sophia Genetics Sa's earnings presentation, Mar 3, 2026
Slide 1: Company Overview: The AI Platform for Precision Medicine
Company Overview The AI Platform for Precision Medicine March 3, 2026
Slide 2: Cautionary notices
Cautionary notices This presentation contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, pro
Slide 3: Building the Intelligence Layer for Precision Medicine
Building the Intelligence Layer for Precision Medicine Actionable Insights Healthcare generates more data than any other industry. Yet decisions are still made under uncertainty. Ai-native SOPHiA DDMTM is the intelligence layer Platform that turns healthcare data into actionable insights. Our Ai-nat
Slide 4: The AI Platform for Precision Medicine
The AI Platform SOPHiA DDMTM –for thePrecision Medicine Ai Platform for Precision Medicine FIRST PRINCIPLES Based in the cloud Tech agnostic No exclusivity with any institution Platform interface Application menu Break data silos Share knowledge and expertise Ai Factories Generate insights using Ai
Slide 5: SOPHiA DDM Connects One of the Largest Data Networks in Healthcare
SOPHiA DDMTM Connects One of the Largest Data Networks in Healthcare For 15 years, we have gone institution to institution connecting genomic analytics onto a single Platform. Today, SOPHiA DDMTM connects 1,000+ institutions across 75 countries, leveraging network effects to power one of the largest
Slide 6: How SOPHiA DDM is Used Every Day
How SOPHiA DDMTM is Used Every Day SOPHiA CUSTOMERS BIOLOGICAL DATA TYPICAL GENOMICS WORKFLOW INSIGHTS FOR INSIGHTS INSIGHTS FOR FOR CLINICAL INSIGHTS FOR INSIGHTS FOR UNIVERSITY UNIVERSITY UNIVERSITY MORE ACCURATEMORE ACCURATE MORE ACCURATE UNIVERSITY HOSPITALS HOSPITALS HOSPITALS DATA Based in the
Slide 7: Why Customers Choose SOPHiA DDM
Why Customers Choose SOPHiA DDMTM 7 © SOPHiA GENETICS 2026 Note: The benefits described above are illustrative and may vary depending on specific use cases and customer circumstances. Results are not guaranteed and may not be representative of all customer experiences. Past outcomes do not guarantee
Slide 8: Strong, Multi-Year Revenue and Volume Growth
Strong, Multi-Year Revenue and Volume Growth Revenue, 2020 – 2025 Analysis volume, 2020 – 2025 391K+ $77M+ 352K $65.2M 312K $62.4M 246K $47.6M 210K $40.5M 163K $28.4M 2020 2021 2022 2023 2024 2025 2020 2021 2022 2023 2024 2025 22% CAGR since 2020 One of the most widely used Ai Platforms in healthcar
Slide 9: SOPHiA's Growth Algorithm
SOPHiA’s Growth Algorithm Growth lever Recent updates as of Q4 Earnings on March 3, 2026 Leveraging data, • Signed 3 new contracts with AstraZeneca (“AZ”) in H2 2025 BioPharma network, and Ai to • Multi-year Ai breast cancer AZ project is “largest in company history” serve BioPharma • Announced part
Slide 10: Land and Expand Growth Engine
Land and Expand Growth Engine Land Expand Analysis volume by customer cohort, 2015 – 2025, ’000s 124 ↑ New customers signed CAGR Expansion Cohort 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 multiple in FY 2025 2015 cohort 19K 32K 42K 49K 52K 46K 51K 54K 64K 67K 71K 14% 3.7x 2016 cohort -
Slide 11: Substantial Volume and Data Growth
Substantial Volume and Data Growth Analysis volume by application type from 2015 – 2025 Data processed by SOPHiA DDMTM from 2021 to 2025 Analysis volume in 000s +40% Volume growth is being driven by sophisticated new Data compute is increasing materially, driven by volume apps such as Liquid Biopsy
Slide 12: 2026 Growth Drivers
2026 Growth Drivers BioPharma Continue Strong Growth in Land and Expand with New Leverage the data and Ai from the U.S. Market Applications in Liquid Biopsy SOPHiA’s network to serve and Solid Tumor BioPharma • U.S. market is significantly • Signed over 70 customers to the • Signed 3 new contracts w
Slide 13: Delivering Value to Patients and Shareholders
Delivering Value to Patients and Shareholders ~$40B+ market opportunity1 Market leading 2,000+ 1,000+ Ai $450M+ technology scientific Customers across native since invested in our Ai publications 75 countries founding since inception FY 2025 highlights Figures as of Dec 31, 2025 67 <1% +124 +30 NPS
Slide 14: Appendix
Appendix
Slide 15: Reconciliation of IFRS to Adjusted Gross Profit and Gross Profit Margin
Reconciliation of IFRS to Adjusted Gros Profit and Gross Profit Margin 2024 2025 (Amounts in USD Thousands) Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY IFRS Revenue $15,779 $15,808 $15,853 $17,733 $65,173 $17,779 $18,323 $19,462 $21,707 $77,271 Gross Profit $10,405 $10,776 $10,654 $12,102 $43,937 $12,208 $12,270
Slide 16: Reconciliation of IFRS Revenue Growth to Constant Currency Revenue Growth
Reconciliation of IFRS Revenue Growth to Constant Currency Revenue Growth (Amounts in USD Thousands) Q4 2024 Q4 2025 Y-o-Y Growth IFRS Revenue $17,733 $21,707 22% Current Period Constant Currency Impact (1) — (1,119) Constant Currency Revenue $17,733 $20,588 16% Presentation of Constant Currency Rev
Slide 17: Reconciliation of IFRS Net Loss to Adjusted EBITDA
Reconciliation of IFRS Net Loss to Adjusted EBITDA (Amounts in USD Thousands) Q4 2024 Q4 2025 IFRS loss for the period ($15,158) ($19,179) Exclude the impact of: Depreciation $1,136 $1,027 Amortization $1,152 $1,411 Interest income ($655) ($381) Interest expense $681 $1,673 Fair value adjustments on